#PREPROS FILTER SERIES#

Unfortunately, erlotinib has shown only minimal efficacy as a single agent, and it has not enhanced the effects of chemotherapy or bevacizumab when combined with these agents. Erlotinib has been evaluated as a single agent in recurrent ovarian cancer, as well as in combination with chemotherapeutic agents in the first-line and recurrent settings, and in combination with the antiangiogenic agent bevacizumab in the recurrent setting, as well as in the maintenance setting after completion of first-line chemotherapy. A number of strategies to block EGFR activity have been developed, including small-molecular-weight tyrosine kinase inhibitors such as erlotinib. This makes EGFR an attractive therapeutic target in this disease. The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial ovarian cancers and promotes cell proliferation, migration and invasion, and angiogenesis, as well as resistance to apoptosis.

Keywords: Quinazoline, anticancer, EGFR, thymidylate enzyme, DNA inhibition, tubulin polymerization A lot of potential is still hidden which demands to be discovered for upgrading quinazoline derivatives efficacy. This review has shown that quinazoline derivatives can further be explored for the betterment of chemotherapy. These derivatives have shown significant activity against cancer.Ĭonclusion: In cancer therapy, Quinazoline derivatives seems to be quite promising and act through various mechanisms that are well established. It was also found to be involved in disturbing tubulin assembly.įurthermore, quinazoline derivatives have been found to inhibit critical targets such as DNA repair enzyme. Results: Exhaustive literature survey indicated that quinazoline derivatives are associated with properties of inhibiting EGFR and thymidylate enzyme. With special focus on quinazoline moiety, this review offers a detailed account of multiple mechanisms of action of various quinazoline derivatives: inhibition of the DNA repair enzyme system, inhibition of EGFR, thymidylate enzyme inhibition and inhibitory effects for tubulin polymerization by which these derivatives have shown promising anticancer potential. Methods: Recent literature related to quinazoline derivatives endowed with encouraging anticancer potential is reviewed. Objective: The aim of this review is to compile and highlight the developments concerning the anticancer activity of quinazoline derivatives as well as to suggest some new aspects on the expansion of anticancer activity of novel quinazoline derivatives as anticancer agents in the near future. Has been performed on quinazoline and their derivatives for anticancer activity and pharmacological importance of this scaffold has been well established. Quinazoline derivatives have already occupied a crucial place in modern medicinal chemistry.Various research The output of extensive research is that the quinazoline scaffold and its various derivatives can be explored further as a novel class ofĬancer chemotherapeutic agents that has already shown promising activities against different tumours. Therefore, researchers around the globe are involved in the development of more efficient and safer anticancer drugs. Reduction of theĬytotoxicity of drugs to the normal cells is a major problem in anticancer therapy.

#PREPROS FILTER SERIES#

An extensive series of anticancer drugs exists in the market, and studies suggest that these molecules are associated with different types of adverse side effects.

A number of existing antineoplastic medications and treatment regimens are already working in the field and several new compounds are in different phases of clinical trials. Background: Cancer is one of the major causes of worldwide human mortality.

Prepros filter